Evidence map›Paper›PMID 30054708›Full record

ArticleAnnals of hematology2018

Fatigue at baseline is associated with geriatric impairments and represents an adverse prognostic factor in older patients with a hematological malignancy.

F Hofer, K A Koinig, L Nagl, B Borjan, R Stauder

Open access · hybridAbstract read
In one paragraph

Article in Annals of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021
    Trial
  5. Protein intake, weight loss, dietary intervention, and worsening of quality of life in older patients during chemotherapy for cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Sleep problems and their interaction with physical activity and fatigue in hematological cancer patients during onset of high dose chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

F HoferDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.
K A KoinigDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.
L NaglDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.
B BorjanDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.
R StauderDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria. reinhard.stauder@i-med.ac.at.
Innsbruck Medical University · AT

Funding

Austrian Science Fund 1576
6 · The paper itself

Abstract

Prospective data on fatigue in elderly persons with a hematological malignancy are rare. We aimed to determine the prevalence of fatigue and its association with clinical outcome and geriatric impairments in older individuals newly diagnosed with blood cancer. The EORTC QLQ-C30 and a multidimensional geriatric assessment (MGA) were performed in parallel in 149 consecutive patients aged > 67 years (median 77.8 years) at Innsbruck Medical University between January 2009 and April 2016. Fatigue as defined by EORTC QLQ-C30 was the most prevalent symptom (84%) and was significantly associated with self-reported role and physical functioning, global health status and insomnia, dyspnea, and loss of appetite (p < 0.001). Remarkably, pronounced fatigue was associated with impaired performance status and objective functional capacities in MGA, with altered depression scoring, G8 screening, and elevation of serum inflammation markers (p < 0.001). Patients with minor fatigue had a median overall survival (OS) of 26.4 months, whereas those with marked fatigue displayed an OS of 7.0 months (p < 0.001). The association between fatigue and shortened OS was supported in multivariate analyses (HR 1.74, CI 1.09-2.76; p = 0.021). Fatigue is seen to have a high prevalence and to be an adverse prognostic factor in elderly patients with a hematological malignancy. The strong impact of fatigue on clinical performance and OS emphasizes the relevance of patient-reported outcomes in individualized treatment algorithms. Patients will benefit from identification of fatigue, allowing timely interventions. The correlation between fatigue, impaired performance, nutritional status, and inflammation might suggest an underlying common pathway.

Indexed as

AgingHealth Services for the AgedAgedAged, 80 and overAge FactorsDisease-Free SurvivalFemaleHematologic NeoplasmsHumansMaleMiddle AgedSurvival RateFatigueGeriatric assessmentHematological malignanciesPatient-reported outcomesQuality of life

Identifiers

PMID30054708
PMCPMC6182757
OpenAlexW2883176590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.